187 related articles for article (PubMed ID: 27720731)
21. 3+4 = 6? Implications of the stratification of localised Gleason 7 prostate cancer by number and percentage of positive biopsy cores in selecting patients for active surveillance.
Ruiz-Cerdá JL; Lorenzo Soriano L; Ramos-Soler D; Marzullo-Zucchet L; Loras Monfort A; Boronat Tormo F
Actas Urol Esp (Engl Ed); 2018 Mar; 42(2):103-113. PubMed ID: 28919101
[TBL] [Abstract][Full Text] [Related]
22. Increase in Prostate Cancer Metastases at Radical Prostatectomy in the United States.
Hu JC; Nanus DM; Sedrakyan A
Eur Urol; 2017 Jan; 71(1):147-149. PubMed ID: 27402061
[No Abstract] [Full Text] [Related]
23. Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility.
Schiffmann J; Wenzel P; Salomon G; Budäus L; Schlomm T; Minner S; Wittmer C; Kraft S; Krech T; Steurer S; Sauter G; Beyer B; Boehm K; Tilki D; Michl U; Huland H; Graefen M; Karakiewicz PI
Urol Oncol; 2015 Jul; 33(7):329.e13-9. PubMed ID: 25960411
[TBL] [Abstract][Full Text] [Related]
24. Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.
Han JS; Toll AD; Amin A; Carter HB; Landis P; Lee S; Epstein JI
Urology; 2012 Oct; 80(4):883-8. PubMed ID: 22921697
[TBL] [Abstract][Full Text] [Related]
25. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
Schenk JM; Newcomb LF; Zheng Y; Faino AV; Zhu K; Nyame YA; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW
J Urol; 2020 Apr; 203(4):727-733. PubMed ID: 31651227
[TBL] [Abstract][Full Text] [Related]
26. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
27. Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens.
Sauter G; Steurer S; Clauditz TS; Krech T; Wittmer C; Lutz F; Lennartz M; Janssen T; Hakimi N; Simon R; von Petersdorff-Campen M; Jacobsen F; von Loga K; Wilczak W; Minner S; Tsourlakis MC; Chirico V; Haese A; Heinzer H; Beyer B; Graefen M; Michl U; Salomon G; Steuber T; Budäus LH; Hekeler E; Malsy-Mink J; Kutzera S; Fraune C; Göbel C; Huland H; Schlomm T
Eur Urol; 2016 Apr; 69(4):592-598. PubMed ID: 26542947
[TBL] [Abstract][Full Text] [Related]
28. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
[TBL] [Abstract][Full Text] [Related]
29. Advancing Age and the Odds of Upgrading and Upstaging at Radical Prostatectomy in Men with Gleason Score 6 Prostate Cancer.
Leeman JE; Chen MH; Huland H; Graefen M; D'Amico AV; Tilki D
Clin Genitourin Cancer; 2019 Dec; 17(6):e1116-e1121. PubMed ID: 31601512
[TBL] [Abstract][Full Text] [Related]
30. Prostate volume effect on Gleason score upgrading in active surveillance appropriate patients.
Çamur E; Coşkun A; Kavukoğlu Ӧ; Can U; Kara Ö; Develi Çamur A; Sarıca K; Narter KF
Arch Ital Urol Androl; 2019 Jul; 91(2):. PubMed ID: 31266273
[TBL] [Abstract][Full Text] [Related]
31. Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens.
Djavan B; Kadesky K; Klopukh B; Marberger M; Roehrborn CG
Eur Urol; 1998; 33(3):261-70. PubMed ID: 9555550
[TBL] [Abstract][Full Text] [Related]
32. Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason ≤ 6 on biopsy cores.
Seisen T; Roudot-Thoraval F; Bosset PO; Beaugerie A; Allory Y; Vordos D; Abbou CC; De La Taille A; Salomon L
World J Urol; 2015 Jun; 33(6):787-92. PubMed ID: 24985552
[TBL] [Abstract][Full Text] [Related]
33. The increase of stage, grading, and metastases in patients undergoing radical prostatectomy during the last decade.
Beck V; Schlenker B; Herlemann A; Apfelbeck M; Buchner A; Gratzke C; Stief CG; Tritschler S
World J Urol; 2019 Jun; 37(6):1103-1109. PubMed ID: 30225798
[TBL] [Abstract][Full Text] [Related]
34. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
35. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.
Epstein JI; Feng Z; Trock BJ; Pierorazio PM
Eur Urol; 2012 May; 61(5):1019-24. PubMed ID: 22336380
[TBL] [Abstract][Full Text] [Related]
36. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer.
Truong M; Slezak JA; Lin CP; Iremashvili V; Sado M; Razmaria AA; Leverson G; Soloway MS; Eggener SE; Abel EJ; Downs TM; Jarrard DF
Cancer; 2013 Nov; 119(22):3992-4002. PubMed ID: 24006289
[TBL] [Abstract][Full Text] [Related]
37. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery.
Tosoian JJ; Sundi D; Trock BJ; Landis P; Epstein JI; Schaeffer EM; Carter HB; Mamawala M
Eur Urol; 2016 Apr; 69(4):576-581. PubMed ID: 26456680
[TBL] [Abstract][Full Text] [Related]
38. Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy.
Thomas C; Pfirrmann K; Pieles F; Bogumil A; Gillitzer R; Wiesner C; Thüroff JW; Melchior SW
BJU Int; 2012 Jan; 109(2):214-9. PubMed ID: 21592293
[TBL] [Abstract][Full Text] [Related]
39. Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer.
Sanguedolce F; Falagario UG; Castellan P; Di Nauta M; Silecchia G; Bruno SM; Russo D; Treacy PJ; Tewari AK; Montironi R; Carrieri G; Cormio L
Urol Oncol; 2020 Oct; 38(10):793.e19-793.e25. PubMed ID: 32220548
[TBL] [Abstract][Full Text] [Related]
40. Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States.
Weiner AB; Patel SG; Eggener SE
Urol Oncol; 2015 Apr; 33(4):164.e11-7. PubMed ID: 25624093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
